Alpha Tau Medical Ltd. (also known as DRTS in some regions) is a leading medical technology company that focuses on the development of innovative oncology products for safe and effective treatment methods. It is headquartered in Tel Aviv, Israel, and has several representative offices scattered across different parts of the world. The company's primary mission is to change the outlook of cancer treatment, eliminating the pain and prolonged treatment periods associated with traditional procedures.
Alpha Tau Medical was founded in 2016 by Prof. Itzhak Kelson and Dr. Yona Keisari from Tel Aviv University. The duo developed the innovative Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), which is one of the most significant breakthroughs in the field of cancer treatment. This pioneering technology utilizes high-energy alpha particles to deliver a high dose of radiation to kill tumor cells effectively. The Alpha DaRT technology has shown impressive success rates in clinical trials on skin, breast, and other forms of cancer.
One of the notable aspects of Alpha Tau Medical's novel technique is its ability to minimize the damage to surrounding healthy tissues. This sets it apart from other radiation-based treatments, as it focuses on eliminating tumors while preserving the health and function of the surrounding organs. This "targeted" approach has brought a lot of positive attention to the company and has placed it at the forefront of cancer research and treatment.
Alpha Tau Medical has garnered widespread recognition and investment due to its groundbreaking research and the promise its technology holds for the future of cancer treatment. It has attracted investors globally, including from the Li Ka Shing Foundation and OurCrowd.
The company's commitment to revolutionizing cancer treatment extends to their partnerships with various medical institutions across North America, Europe, and Asia, where Alpha Tau's treatment is currently undergoing numerous additional clinical trials. It anticipates regulatory approval in Europe and Canada in the near future.
While still a relatively young company, Alpha Tau Medical Ltd. has shown a promising trajectory and is set to become a game-changer in the world of oncology. The marriage of high-tech science, innovative thinking, and a commitment to improving patient outcomes puts Alpha Tau Medical in a unique position in the fight against cancer. It is with this passion and promising technology that Alpha Tau Medical Ltd. continues its mission towards a future without devastating encounters with cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Alpha Tau Medical Ltd. has signed a Memorandum of Understanding (MOU) with Samsung Medical Center (SMC) in Seoul, South Korea, to explore a potential clinical trial for its Alpha DaRT® therapy in pancreatic cancer patients. This collaboration aims to address the high mortality rate and limited treatment options for pancreatic cancer in Korea, where SMC is a leading oncology center. The potential trial, Alpha DaRT’s first in South Korea, would be subject to regulatory and ethics committee approvals.
Alpha Tau Medical (DRTS) recently received FDA approval to expand its U.S. REGAIN trial for recurrent glioblastoma, increasing patient enrollment and adding new endpoints. This move signals a deeper investment in clinical evidence for their Alpha DaRT platform, potentially impacting development timelines, costs, and future regulatory discussions. The expansion creates new catalysts but also heightens the risk associated with its costly development push for the clinical-stage firm, which currently has no revenue.
The FDA has approved an expansion of Alpha Tau Medical's U.S. brain cancer trial (REGAIN) for recurrent glioblastoma, doubling the permitted enrollment to 20 patients and adding progression-free survival and quality-of-life assessments. This decision comes as Alpha Tau prepares to present new REGAIN trial data on November 13, building on promising early results from the first three patients which showed significant tumor responses. The expansion aims to further investigate if early imaging results translate into broader clinical benefits for patients with this aggressive form of brain cancer.